Munich
,
Germany
30 November - 1 December 2023
Congress on Cardiovascular, Kidney and Metabolic Outcomes (CVOT Summit 2023)
Presentation schedule and materials
Thursday, 30 November 2023
15:00
CET
Publication
Liver fibrosis is associated with cardiovascular disease burden amongst patients with non-alcoholic steatohepatitis: the unCoVer-NASH longitudinal cohort study
Elisabetta Bugianesi1; Kathleen E. Corey2; Anurag Mehta3; Kamal Kant Mangla4; Abhishek Shankar Chandramouli5; Ahsan Shoeb Patel4; Sharat Varma4
15:00
CET
Publication
Safety profile of semaglutide in patients with metabolic dysfunction-associated steatohepatitis: post-hoc analysis of data from two phase 2 studies
Lise Lotte Gluud1; Stephen A. Harrison2; Maximilian Kurt Jara3; Mette Skalshøi Kjær4; Amine Lotfi4; Karina Phonekeo4; Mads Sundby Palle4; Philip N. Newsome5
15:00
CET
Publication
Semaglutide and Kidney Function: Analysis of Three Randomised Trials in Non-Alcoholic Fatty Liver Disease
Katherine R. Tuttle1; Thomas Idorn2; Maximilian Jara2; Mads Sundby Palle2; Anne-Sophie Sejling2; Rahma Elmahdi2; Henning Grønbæk3
MATERIALS AVAILABLE
15:00
CET
Publication
Once-Weekly Subcutaneous Semaglutide in Carotid Atherosclerotic Inflammation in Type 2 Diabetes and Cardiovascular Disease: Study Methods and Baseline Results
Stefan James1; Andreas D Christoffersen2; Jens-Peter David2; Maria D Radu Juul Jensen2; Linda Mellbin3; Thomas R Pieber4; Rasmus S Ripa5; Peter Rossing6; Andreas Kjær5
Friday, 01 December 2023
17:30
- 18:30
CET
OP 6
Publication
Change in Fibrosis-4 Index (FIB4) is associated with risk of liver events, cardiovascular events, and all-cause mortality in patients with obesity and/or type 2 diabetes (T2D)
Kamlesh Khunti1; Tina L. Berentzen2; Louise M. Nitze2; Maximilian Jara2; Anders Jensen2; Mette S. Kjær2; Kamal K. Mangla2; Jens M. Tarp2; Quentin M. Anstee3,4
17:30
- 18:30
CET
OP 7
Publication
Prevalence and effect of semaglutide on non-alcoholic steatohepatitis in people with obesity with and without type 2 diabetes: analyses from the STEP 1 and 2 trials using SomaSignal tests
Michelle T. Long1; Jörn M. Schattenberg2; Henning Grønbæk3; Iris Kliers1; Steen Ladelund1; Sune Boris Nygård1; Arun J. Sanyal4; Melanie Davies5,6
Keywords